Global Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, α-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others),By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography –Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 

Market Outline: Anti diabetic Biosimilars Market

 

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

 

Market Dynamics: Anti diabetic Biosimilars Market

Drivers:

• Increase in the prevalence of diabetic patients
• Patent expiries block buster drugs and promising product pipeline
• Government initiations to control the diabetes

Restraints:

• High cost of R&D activities
• Stringent regulatory policies
• Complexity in development of biosimilars

 

Market Scope: Anti diabetic Biosimilars Market

Global anti-diabetic biosimilars market is segmented on the basis of drug class, disease type, distribution channel, and region

Based on the drug class, anti-diabetic biosimilars market is segmented into the following:

• Insulin
• Biguanides
• Sulfonyl Ureas
• Thiazolidinediones
• Di Peptidyl Peptidase (DPP)-IV Inhibitors
• α-glucosidase Inhibitos
• GLP-1 Agonists
• Others

Based on the disease type, anti-diabetic biosimilars market is segmented into the following:

• Type-I Diabetes
• Type-II Diabetes

Based on the distribution channel, anti-diabetic biosimilars market is segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the region, anti-diabetic biosimilars market is segmented into the following:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

 

Competition Assessment: Anti diabetic Biosimilars Market

Some of the players in the global anti-diabetic biosimilars market include:

• Biocon (India)
• Merck Sharp & Dohme Corporation (U.S.)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly & Co. (U.S.)
• Sanofi-aventis U.S. LLC (U.S.)
• Samsung Bioepis (Samsung BioLogics) (South Korea)
• Mylan N.V. (U.S.)
• Wockhardt (India)

 

Notable Market Developments: Anti-diabetic Biosimilars Market

• In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar

 

Key Features of the Report:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key marketdevelopments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

• Biocon (India)
• Merck Sharp & Dohme Corporation (U.S.)
• Boehringer Ingelheim GmbH (Germany)
• Eli Lilly & Co. (U.S.)
• Sanofi-aventis U.S. LLC (U.S.)
• Samsung Bioepis (Samsung BioLogics) (South Korea)
• Mylan N.V. (U.S.)
• Wockhardt (India)

1. Executive Summary

 

2. Global Anti diabetic Biosimilars Market Introduction

 

2.1. Global Anti diabetic Biosimilars Market– Taxonomy

2.2. Global Anti diabetic Biosimilars Market–Definitions

2.2.1. Drug Class

2.2.2. Disease Type

2.2.3. Distribution Channel

 

3. Global Anti diabetic Biosimilars Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Anti diabetic Biosimilars Market Dynamic Factors – Impact Analysis

3.6. Global Anti diabetic Biosimilars Market– Competition Landscape

3.7. Epidemiology

 

4. Global Anti diabetic Biosimilars MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market OpportunityAnalysis

 

5. Global Anti diabetic Biosimilars Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

5.1. Insulin

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Biguanides

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Sulfonyl Ureas

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Thiazolidinediones

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

5.6. α-glucosidase Inhibitos

5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.6.3. Market Opportunity Analysis

5.7. GLP-1 Agonists

5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.7.3. Market Opportunity Analysis

5.8. Others

5.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.8.3. Market Opportunity Analysis

 

6. Global Anti diabetic Biosimilars Market Forecast, By Disease Type, 2013 – 2017 and Forecast, 2017 – 2024

 

6.1. Type-I Diabetes

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Type-II Diabetes

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

 

7. Global Anti diabetic Biosimilars Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

 

8. Global Anti diabetic Biosimilars Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

 

9. North America Anti diabetic Biosimilars Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

9.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Insulin

9.1.2. Biguanides

9.1.3. Sulfonyl Ureas

9.1.4. Thiazolidinediones

9.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

9.1.6. α-glucosidase Inhibitos

9.1.7. GLP-1 Agonists

9.1.8. Others

9.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Type-I Diabetes

9.2.2. Type-II Diabetes

9.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

9.6. North America Anti diabetic Biosimilars Market Dynamics – Trends

 

10. Europe Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Insulin

10.1.2. Biguanides

10.1.3. Sulfonyl Ureas

10.1.4. Thiazolidinediones

10.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

10.1.6. α-glucosidase Inhibitos

10.1.7. GLP-1 Agonists

10.1.8. Others

10.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Type-I Diabetes

10.2.2. Type-II Diabetes

10.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

10.6. Europe Anti diabetic Biosimilars Market Dynamics – Trends

 

11. Asia-Pacific Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Insulin

11.1.2. Biguanides

11.1.3. Sulfonyl Ureas

11.1.4. Thiazolidinediones

11.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

11.1.6. α-glucosidase Inhibitos

11.1.7. GLP-1 Agonists

11.1.8. Others

11.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Type-I Diabetes

11.2.2. Type-II Diabetes

11.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

11.6. Asia-Pacific Anti diabetic Biosimilars Market Dynamics – Trends

 

12. Latin America Anti diabetic Biosimilars Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Insulin

12.1.2. Biguanides

12.1.3. Sulfonyl Ureas

12.1.4. Thiazolidinediones

12.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

12.1.6. α-glucosidase Inhibitos

12.1.7. GLP-1 Agonists

12.1.8. Others

12.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Type-I Diabetes

12.2.2. Type-II Diabetes

12.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

12.6. Latin America Anti diabetic Biosimilars Market Dynamics – Trends

 

13. Middle East and Africa Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Insulin

13.1.2. Biguanides

13.1.3. Sulfonyl Ureas

13.1.4. Thiazolidinediones

13.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors

13.1.6. α-glucosidase Inhibitos

13.1.7. GLP-1 Agonists

13.1.8. Others

13.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Type-I Diabetes

13.2.2. Type-II Diabetes

13.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024

13.6. MEA Anti diabetic Biosimilars Market Dynamics – Trends

 

14. Competition Landscape

 

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Biocon (India)

14.2.2. Merck Sharp & Dohme Corporation (U.S.)

14.2.3. Boehringer Ingelheim GmbH (Germany)

14.2.4. Eli Lilly & Co. (U.S.)

14.2.5. Sanofi-aventis U.S. LLC (U.S.)

14.2.6. Samsung Bioepis (Samsung BioLogics) (South Korea)

14.2.7. Mylan N.V. (U.S.)

14.2.8. Wockhardt (India)

 

15. Research Methodology

16. Key Assumptions and Acronyms

 

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

ASK AN ANALYST